ResearcherSecond Affiliated Hospital of Zhejiang UniversityNo recent work listed
Jiangtao Li
Matched on ORCID iD 0000-0001-7538-2910; OpenAlex author ID A5100426827. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper
Papers 3
- Is it justified to assess the resectability of pancreatic cancer combined with biological and conditional factors? Last author DOI 10.21037/tcr-22-1258↗
- The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
- Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Bingying Huang · 1 shared paper, 2022 · strength 0.15
- Jinhong Wu · 1 shared paper, 2022 · strength 0.15
- Yun Jin · 1 shared paper, 2022 · strength 0.15
- Quanxing Ni · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Bei Sun · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Defei Hong · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Gang Zhao · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Shengping Li · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Jian Wang · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Yongwei Sun · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Yixiong Li · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Xianjun Yu · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Wei Wang · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Rufu Chen · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Jihui Hao · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Weilin Wang · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Chenghao Shao · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Bole Tian · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Renyi Qin · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Yiping Mou · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Deliang Fu · 2 shared papers, 2015–2016 · strength 0.08
- Paper The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates … DOI 10.3892/ijo.2015.3316↗
- Paper Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resecta… DOI 10.3892/ijo.2015.3128↗
- Jinfeng Xiang · 1 shared paper, 2016 · strength 0.04
- Liang Liu · 1 shared paper, 2016 · strength 0.04
- Jun Zhou · 1 shared paper, 2016 · strength 0.04
- Liwei Wang · 1 shared paper, 2016 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.